Evaluation of Complication, Renal Function, and Recurrence‐Free Survival in Hilar and Non‐Hilar Tumors During Robot‐Assisted Partial Nephrectomy: A Propensity Score‐Matched Analysis
International Journal of Urology · 2025
DOI: 10.1111/iju.70156 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Kentaro Muraoka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Yokohama City University Hospital, Kanazawa-ku, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Nephrectomy, Robotic Surgical Procedures, Kidney Neoplasms, Postoperative Complications. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objective
To compare complications, perioperative outcomes, postoperative renal function, and recurrence‐free survival (RFS) between robot‐assisted partial nephrectomy (RAPN) for hilar and non‐hilar tumors.
Methods
We retrospectively analyzed the medical records of patients who underwent RAPN between March 2016 and August 2023. Patient demographic characteristics were adjusted using 1:1 propensity score matching.
Results
A total of 618 patients (524 with non‐hilar tumors and 94 with hilar tumors) were analyzed. Hilar tumors exhibited a larger tumor size, higher RENAL nephrometry score ( RNS ), and greater complexity than non‐hilar tumors pre‐matching (all p < 0.05). Propensity score matching resulted in 77 patients per group, with no significant baseline differences except for the L factor of the RNS . Before propensity score matching, hilar tumors were associated with a higher frequency of renal artery/vein clamping and intraperitoneal approaches, as well as significantly longer operative and warm ischemia times than non‐hilar tumors. However, after matching, these differences were no longer significant. The adverse event rate was not significantly different between the hilar and non‐hilar tumor groups. Trifecta achievement rates were significantly lower in hilar tumors before matching ( p < 0.001) but were comparable after matching ( p = 0.325). No significant differences were observed in the postoperative eGFR , preservation at 1, 3, and 12 months, or pentafecta rates. Before matching, RFS was significantly lower in hilar tumors ( p = 0.015); however, this difference was not significant after matching ( p = 0.186).
Conclusion
Hilar tumors showed similar complications, renal function, and recurrence‐free survival rates as non‐hilar tumors, indicating that RAPN is safe and feasible for hilar tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Yokohama City University Hospital, Kanazawa-ku, Yokohama, Kanagawa, Japan.
ORCID-Profile: Kentaro Muraoka, Tomoyuki Tatenuma, Kazuhide Makiyama
Zitieren
APA
Muraoka, K., Takeya, D., Nishimura, K., Honda, S., Numata, Y., Kobayashi, K., Jikuya, R., Tatenuma, T., Noguchi, G., Ueno, D., Komeya, M., Ito, H., Ito, Y., Hasumi, H., & Makiyama, K. (2025). Evaluation of Complication, Renal Function, and Recurrence‐Free Survival in Hilar and Non‐Hilar Tumors During Robot‐Assisted Partial Nephrectomy: A Propensity Score‐Matched Analysis. International Journal of Urology. https://doi.org/10.1111/iju.70156
Vancouver
Muraoka K, Takeya D, Nishimura K, Honda S, Numata Y, Kobayashi K, et al. Evaluation of Complication, Renal Function, and Recurrence‐Free Survival in Hilar and Non‐Hilar Tumors During Robot‐Assisted Partial Nephrectomy: A Propensity Score‐Matched Analysis. International Journal of Urology. 2025. doi:10.1111/iju.70156
BibTeX
@article{Muraoka2025,
author = {Muraoka, Kentaro and Takeya, Daiki and Nishimura, Kazuhiro and Honda, Seiichiro and Numata, Yasuhiro and Kobayashi, Kota and Jikuya, Ryosuke and Tatenuma, Tomoyuki and Noguchi, Go and Ueno, Daiki and Komeya, Mitsuru and Ito, Hiroki and Ito, Yusuke and Hasumi, Hisashi and Makiyama, Kazuhide},
title = {Evaluation of Complication, Renal Function, and Recurrence‐Free Survival in Hilar and Non‐Hilar Tumors During Robot‐Assisted Partial Nephrectomy: A Propensity Score‐Matched Analysis},
journal = {International Journal of Urology},
year = {2025},
doi = {10.1111/iju.70156}
}
EUVIMED